Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 19/20 | 0.83 |
| ▸ | CCNH | P51946 | 10/20 | 0.61 |
| ▸ | CCNK | O75909 | 7/20 | 0.61 |
| ▸ | CDK12 | Q9NYV4 | 7/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.61 |
| ▸ | CDK9 | P50750 | 7/20 | 0.61 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.61 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16654912 | 0.92 | CDK7 (0.83) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL16654908 | 0.92 | CDK7 (0.83) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL17688383 | 0.91 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL22778394 | 0.91 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CCNT1 | |
| Hydrochloric Acid SCHEMBL16655187 | 0.90 | CDK7 (0.98) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL16665127 | 0.90 | CDK7 (0.70) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL18072740 | 0.89 | CDK7 (0.77) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL18047348 | 0.87 | CDK7 (0.74) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL16665185 | 0.87 | CDK7 (0.74) | CDK7CCNHCCNKCDK12CCNT1 | |
| SCHEMBL16665150 | 0.84 | CDK7 (0.84) | CDK7CCNHCCNKCDK12CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2016058544-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CCNH 42/4885CCNK 19/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 32/4885CCNK 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.